- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03957707
Sterotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation (SOITBE)
November 16, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sterotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation: a Randomized Controlled Trial.
Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases.
Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage.
Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established.
Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications.
Our hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration.
So we conduct a prospective multicenter randomized controlled clinical trial to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small to moderate hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
360
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- gao chen
- Phone Number: 8613805716226
- Email: d-gaochen@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a volume < 30 mL calculated by ABC/2 formula and Glasgow Coma Scale score ≥ 9.
- With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength ≤ grade 3 or NIHSS score ≥ 15 points.
- Hematoma stability shown by a CT scan at least 6 hours after the diagnostic CT (hematoma volume increase < 5 ml by ABC/2 formula)
- Diagnostic CT scan should be obtained within 24 hours after the onset of symptoms. Cases with unclear onset time should be excluded.
- Randomization within 72 hours after diagnostic CT.
- Surgery should be performed within 72 hours after onset.
- SBP <180 mmHg maintained for 6 hours prior to randomization.
- Age between 18-70 years old.
- mRS score ≤ 1 in past medical history.
- Patients who are suitable and willing to be randomized to "puncture aspiration + urokinase" or conservative medical treatment.
Exclusion Criteria:
- Hematoma involves other structures such as the thalamus and midbrain.
- Mass effect or hydrocephalus due to intraventricular hemorrhage.
- Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation (AVM) and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage.
- Manifestation of early stage cerebral herniation such as ipsilateral pupil changes and midline shift exceeding 1 cm.
- Patients with unsteady hematoma or with progression to intracranial hypertension syndrome.
- Patients with any irreversible coagulopathy or known coagulation disorders; platelet count <100,000; INR > 1.4.
- Patients requiring long-term use of anticoagulants.
- Patients taking dabigatran, apixaban and/or rivaroxaban (or similar drugs of the same category) before symptoms arise.
- Bleeding in other sites, including retroperitoneal, gastrointestinal, genitourinary or respiratory tract bleeding; superficial or skin surface bleeding mainly occurring in the vascular puncture site or transvenous approach (eg. arterial puncture, venous incision, etc. ) or in the recent surgical site.
- May be pregnant in the near future or already pregnant.
- Previously enrolled in this study.
Participating in other interventional medical research or clinical trials at the same time.
Patients enrolled in observational, natural history and/or epidemiological studies (without intervention) are eligible for this trial.
- Patients with an expected survival of less than 6 months.
- Patients with severe co-morbidity (including hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which may affect the outcome assessment.
- Patients with mechanical heart valve. Biological valves are acceptable.
- Patients with risk of embolism (including a history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is acceptable.
- Investigators believe co-morbidities would be detrimental to the patient when the study begins.
- Patients difficult to follow up or with poor compliance due to various reasons (such as geographical and social factors, drug or alcohol abuse, etc.)
- Patient or his or her legal guardian/representative is unable or unwilling to give the written informed consent.
- Patients is in a condition that is not suitable for "puncture aspiration + urokinase" treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: stereotactic surgery with drugs treatment
|
stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
|
SHAM_COMPARATOR: drugs treatment alone
|
stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of ADL score
Time Frame: 6 months
|
ADL: Activities of Daily Living, ranges from 0-100, a higher ADL score means a better situation.
|
6 months
|
improvement of muscle strength of the hemiplegic limb or aphasia
Time Frame: 6 months
|
6 months
|
|
Changes in GOS score
Time Frame: 6 months
|
GOS: Glasgow Outcome Scale, ranges from 1-5, a higher GOS score means a better situation.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality rate
Time Frame: 6 months
|
6 months
|
|
Hematoma clearance rate
Time Frame: 1 day and one month
|
1 day and one month
|
|
Change in GCS score
Time Frame: one month
|
GCS: Glasgow Coma Scale, ranges from 3-15, a higher GCS score means a better situation.
|
one month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2019
Primary Completion (ANTICIPATED)
December 31, 2021
Study Completion (ANTICIPATED)
December 31, 2021
Study Registration Dates
First Submitted
May 19, 2019
First Submitted That Met QC Criteria
May 19, 2019
First Posted (ACTUAL)
May 21, 2019
Study Record Updates
Last Update Posted (ACTUAL)
November 17, 2021
Last Update Submitted That Met QC Criteria
November 16, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Cysts
- Connective Tissue Diseases
- Basal Ganglia Diseases
- Mucinoses
- Intracranial Hemorrhages
- Basal Ganglia Cerebrovascular Disease
- Cerebral Hemorrhage
- Hemorrhage
- Ganglion Cysts
- Synovial Cyst
- Hematoma
- Basal Ganglia Hemorrhage
Other Study ID Numbers
- 2018-222
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Ganglia Haematoma
-
Assiut UniversityNot yet recruitingBasal Ganglionic Hemorrhage
-
Second Affiliated Hospital, School of Medicine,...First Affiliated Hospital of Fujian Medical University; Taizhou Hospital; The... and other collaboratorsRecruitingBasal Ganglia HematomaChina
-
Clearmind Biomedical Inc.Chang Gung Memorial HospitalCompletedCerebral Hemorrhage | Intracerebral Hemorrhage | Basal Ganglia Hemorrhage | Intracranial HemorrhageTaiwan
-
Centre Hospitalier Universitaire DijonCompletedSubretinal Haematoma Linked to AMDFrance
-
Peking University Third HospitalRecruitingBasal Ganglia HemorrhageChina
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Anhui Medical University; Huashan Hospital; China-Japan... and other collaboratorsNot yet recruiting
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
University of Rome Tor VergataCompletedBreast Cancer | Breast Diseases | Breast HaematomaItaly
-
University Hospital, GrenobleCompletedQuality of Life | Craniectomy | Handicaps Physical | Cerebellar Haematoma | Handicap MentalFrance
-
Ain Shams UniversityCompletedLocal Anesthetic Toxicity | Injection Site HaematomaEgypt
Clinical Trials on stereotactic surgery plus thrombolysis
-
Lawson Health Research InstituteActive, not recruitingNon Small Cell Lung CancerCanada
-
University of Toledo Health Science CampusWithdrawnPost Thrombotic Syndrome | Deep Venous ThrombosisUnited States
-
The First Affiliated Hospital of University of...Not yet recruiting
-
National Institute of Cardiovascular Diseases,...East Slovakia Institute of Cardiovascular Diseases in Košice, Slovakia; Central...CompletedAcute Deep Venous ThrombosisSlovakia
-
Medalp Private Surgery ClinicState Budgetary Healthcare Institution, National Medical Surgical Center...RecruitingDeep Vein Thrombosis | Postthrombotic Syndrome | Pulmonary Embolism | Thromboses, Venous | Thrombosis EmbolismRussian Federation
-
University Health Network, TorontoWithdrawnPatients With a Single Brain Metastasis
-
M.D. Anderson Cancer CenterCompletedBrain CancerUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownNeoplasm MetastasisIsrael
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
National Institute of Neurological Disorders and...CompletedNeoplasm Metastasis | Brain NeoplasmsUnited States